Pregnancy prevention programme guidance for patients receiving the teratogenic drugs thalidomide, lenalidomide (Revlimid) and pomalidomide (Imnovid) has been changed temporarily during the COVID-19 pandemic, advises the UK Medicines and Healthcare products Regulatory Authority (MHRA).

The MHRA has agreed with the drug manufacturer Celgene to temporarily modify pregnancy prevention programmes to allow home pregnancy testing and remote consultations during the COVID-19 lockdown period. While COVID-19 measures are in place, pregnancy testing by the patient at home is permitted, at the discretion of the clinician, provided the following criteria are met: adequate instruction and support are provided; pregnancy tests meet the minimum sensitivity of 25 mIU/mL; and the result of each pregnancy test is verified by the prescriber. For prescriber verification, the patient should send a photograph of the test result by email or video conferencing, if possible, or provide a telephone description of the test result, pregnancy testing kit make, and how it was used.

Before starting treatment with thalidomide, lenalidomide or pomalidomide, the patient and prescriber must sign a Treatment Initiation Form (TIF) to confirm that they both agree to the conditions of the pregnancy prevention programme, and the prescriber and dispensing pharmacist must complete a Prescription Authorisation Form (TIF) for each prescription of these drugs. While COVID-19 measures are in place, prescribers who determine that a remote consultation is appropriate should contact the pharmacist to obtain electronic versions of TIFs and PAFs which they must complete and return. The patient must receive an educational booklet and a paper copy of the TIF which they should complete and return to the prescriber.
